Cargando…

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes

AIMS: To examine whether insulin glargine can lead to better control of glycated haemoglobin (HbA1c) than that achieved by neutral protamine Hagedorn (NPH) insulin, using a protocol designed to limit nocturnal hypoglycaemia. METHODS: The present study, the Least One Oral Antidiabetic Drug Treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Home, P D, Bolli, G B, Mathieu, C, Deerochanawong, C, Landgraf, W, Candelas, C, Pilorget, V, Dain, M-P, Riddle, M C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282751/ https://www.ncbi.nlm.nih.gov/pubmed/24957785 http://dx.doi.org/10.1111/dom.12329

Ejemplares similares

Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin-naïve Chinese Type 2 Diabetes Patients
por: Ling, James, et al.
Publicado: (2021)

Cost Effectiveness of Insulin Glargine versus Neutral Protamin Hagedorn Insulin in the Treatment of Type 2 Diabetes Patients in Turkey
por: Satman, Ilhan, et al.
Publicado: (2013)

A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus
por: Liu, Min, et al.
Publicado: (2016)

Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study
por: Rosenstock, J., et al.
Publicado: (2009)

Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study
por: Wolnik, B., et al.
Publicado: (2020)

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study
por: Rosenstock, J., et al.
Publicado: (2009)

Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial
por: Bolli, Geremia B., et al.
Publicado: (2020)

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)
por: Bolli, G B, et al.
Publicado: (2015)

Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy
por: Lepercq, Jacques, et al.
Publicado: (2012)

Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study
por: Wang, Li, et al.
Publicado: (2013)

Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A(1)chieve study
por: Wangnoo, Subhash Kumar, et al.
Publicado: (2014)

Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes
por: Rodbard, H W, et al.
Publicado: (2014)

Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis
por: Lau, E., et al.
Publicado: (2019)

Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Reply to Chantelau E [letter] and Currie CJ [letter]
por: Rosenstock, J., et al.
Publicado: (2009)

Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)
por: Home, Philip D., et al.
Publicado: (2017)

Comparable efficacy with similarly low risk of hypoglycaemia in patient‐ vs physician‐managed basal insulin initiation and titration in insulin‐naïve type 2 diabetic subjects: The Italian Titration Approach Study
por: Bonadonna, Riccardo C., et al.
Publicado: (2020)

Neutral protamine hagedorn/regular insulin in the treatment of inpatient hyperglycemia: Comparison of 3 basal-bolus regimens
por: Quintanilla-Flores, Dania Lizet, et al.
Publicado: (2017)

Long‐term field study of lispro and neutral protamine Hagedorn insulins treatment in dogs with diabetes mellitus
por: Kuzi, Sharon, et al.
Publicado: (2023)

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)
por: Matsuhisa, M., et al.
Publicado: (2016)

Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study
por: ji, Jing, et al.
Publicado: (2020)

A meta‐analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia
por: Heller, S., et al.
Publicado: (2015)

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension
por: Yki‐Järvinen, H., et al.
Publicado: (2015)

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension
por: Riddle, M C, et al.
Publicado: (2015)

Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self‐titrating insulin glargine U‐100
por: Hollander, Priscilla A., et al.
Publicado: (2019)

Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12‐month comparison by concomitant sulphonylurea and/or glinide use
por: Terauchi, Yasuo, et al.
Publicado: (2018)

Glucose/insulin-glargine/insulin-lispro: Hepatic glycogenosis, hypoglycaemia and acute hepatitis: case report
Publicado: (2021)

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)
por: Terauchi, Y., et al.
Publicado: (2016)

Protamine Zinc Insulin
por: Bose, J. P.
Publicado: (1938)

Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept’ study
por: Owens, D R, et al.
Publicado: (2011)

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
por: Rosenstock, J., et al.
Publicado: (2008)

Switching from Neutral Protamine Hagedorn (NPH) Insulin to Insulin Glargine 300 U/mL in Older and Younger Patients with Type 2 Diabetes: A Post Hoc Analysis of a Multicenter, Prospective, Observational Study
por: Wolnik, B., et al.
Publicado: (2022)

A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes
por: Hod, Moshe, et al.
Publicado: (2014)

The Mobile Insulin Titration Intervention (MITI) for Insulin Glargine Titration in an Urban, Low-Income Population: Randomized Controlled Trial Protocol
por: Levy, Natalie, et al.
Publicado: (2015)

The Use of Protamine Insulin
por: Nixon, J. A.
Publicado: (1938)

Protamine Zinc Insulin
Publicado: (1937)

Zinc Protamine Insulin
por: Dunlop, D. M.
Publicado: (1938)

Insulin Hypoglycæmia
Publicado: (1948)

Replacement of neutral protamine Hagedorn insulin with the long‐acting insulin analogue, detemir, improves glycemic control without weight gain in basal–bolus insulin therapy in Japanese patients with type 1 diabetes
por: Hayakawa, Taro, et al.
Publicado: (2011)

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study
por: Galstyan, Gagik R., et al.
Publicado: (2022)

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used
por: Norwood, Paul, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_oaoshsf6ru191eif9q9kbfnvnr